ReviewLa Radiologia medica2026
Application advances of habitat imaging based on CT or PET/CT: a systematic review.
Review in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHabitat imaging (HI) enables the identification of tumor heterogeneity and characterization of the tumor microenvironment. Although HI based on MRI is well-established, its implementation using CT or PET/CT remains nascent and underexplored.
objectiveThis systematic review analyzes recent advances in HI based on CT or PET/CT for tumor diagnosis and treatment, evaluating its clinical utility and limitations.
methodsLiteratures were systematically searched in PubMed, Embase, Web of Science, and Cochrane Library. Study quality was assessed using the radiomics quality score (RQS).
resultsA total of 21 studies comprising 7363 patients were included. The number of radiomic features extracted ranged from 41 to 12,838 across studies. Cancer types included lung (47.6%), head and neck (14.3%), renal (14.3%), gastrointestinal (9.5%), ovarian (9.5%), and liver (4.8%). All included studies were retrospective in design. The mean RQS was 15.71 ± 3.06. Common limitations included the absence of scanner simulation studies, prospective validation, cost-effectiveness analyses, and data/code sharing. Furthermore, substantial heterogeneity was observed across studies in terms of image acquisition, segmentation methods, and habitat definitions.
conclusionHI based on CT or PET/CT demonstrates preliminary potential in evaluating treatment response, predicting prognosis, and revealing tumor pathological and molecular characteristics. However, the current evidence is of low-to-moderate quality with a risk of bias, and considerable methodological heterogeneity exists. The overall body of evidence remains at a relatively early stage. Prospective studies are needed to validate HI as a clinical biomarker.
Indexed as
Identifiers
42789168What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.